MOUNTAIN VIEW, Calif., June 13 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS - News), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced that the U.S. Patent and Trademark Office has issued the company's first patent for Qnexa(TM), an investigational, oral treatment for obesity. This patent, number US 7,056,890 B2, broadly covers the Qnexa product and its use in the treatment of obesity. The term of this patent extends into 2019. Qnexa is the subject of multiple additional U.S. and foreign patent applications.
